Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT02999178 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

663

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Diseases, Interstitial

Interventions

DRUG: Nintedanib
DRUG: Placebo

Sponsor

Boehringer Ingelheim